Patrick Eckstrom
Direttore operativo presso Mycrodose Therapeutics, Inc.
Profilo
Patrick Eckstrom currently works as a Chief Operating Officer at Mycrodose Therapeutics, Inc.
Posizioni attive di Patrick Eckstrom
| Società | Posizione | Inizio |
|---|---|---|
Mycrodose Therapeutics, Inc.
 Mycrodose Therapeutics, Inc. BiotechnologyHealth Technology Mycrodose Therapeutics, Inc. is a US-based pharmaceutical company that specializes in developing advanced drug delivery systems using DEA Schedule I & III drugs and other compounds to treat cancer-related conditions, mental health, and cognitive degenerative diseases. Mycrodose Therapeutics is one of the few private companies that have been granted a Schedule I license and approved by the United States Drug Enforcement Agency (DEA), State of Attorney Generals Research Advisory Board, and the US Food & Drug Administration (FDA) to research four psychedelic compounds: psilocybin, LSD, MDMA, and DMT. The company is based in San Diego, CA, and was founded in 2020. The company's IP-protected sustained microdosing technology™ is a safer and smarter approach to delivering pharmaceutical compounds to patients of all ages, allowing for an expandable and scalable business model. Chad S. Conner has been the CEO of the company since 2020. | Direttore operativo | - |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Aziende private | 1 |
|---|---|
Mycrodose Therapeutics, Inc.
Mycrodose Therapeutics, Inc. BiotechnologyHealth Technology Mycrodose Therapeutics, Inc. is a US-based pharmaceutical company that specializes in developing advanced drug delivery systems using DEA Schedule I & III drugs and other compounds to treat cancer-related conditions, mental health, and cognitive degenerative diseases. Mycrodose Therapeutics is one of the few private companies that have been granted a Schedule I license and approved by the United States Drug Enforcement Agency (DEA), State of Attorney Generals Research Advisory Board, and the US Food & Drug Administration (FDA) to research four psychedelic compounds: psilocybin, LSD, MDMA, and DMT. The company is based in San Diego, CA, and was founded in 2020. The company's IP-protected sustained microdosing technology™ is a safer and smarter approach to delivering pharmaceutical compounds to patients of all ages, allowing for an expandable and scalable business model. Chad S. Conner has been the CEO of the company since 2020. | Health Technology |
- Borsa valori
- Insiders
- Patrick Eckstrom
